Video
Dr Matthew Goetz explains the rationale for using CDK4/6 inhibitors in patients with HR-positive metastatic breast cancer. Read More ›
Dr Matthew Goetz addresses the prospect of utilizing CDK4/6 inhibitors to treat patients with HER2+ metastatic breast cancer, stating early data indicate that CDK4/6 inhibitors may have some antitumor activity in HER2+ breast cancer. Read More ›
Despite international guidelines and data that show CDK4/6 inhibitors plus aromatase inhibitors can improve overall response rates, overall survival, and progression-free survival in patients with metastatic breast cancer, there is a lasting belief among patients that chemotherapy is the preferable course of treatment. Dr. Hope Rugo attempts to dispel this misconception, citing that endocrine therapy and CDK4/6 inhibitors are well tolerated and don’t have the intensive side effects associated with chemotherapy. Read More ›
Dr Matthew Goetz reviews what differentiates abemaciclib, the latest CDK4/6 inhibitor FDA-approved for HR+ metastatic breast cancer, from ribociclib and palbociclib. Read More ›
Dr Hope Rugo provides an overview of some hot topics being covered at SABCS 2017 in the areas of hormone therapy, immunotherapy, neoadjuvant therapy, and more. Read More ›
Dr Hope Rugo discusses studies that are aiming to evaluate the effect that CDK4/6 inhibitors have on patients with HER2+ breast cancer. Read More ›
Hope S. Rugo, MD, describes how she would treat a patient with HER-positive metastatic breast cancer that has progressed with a CDK4/CDK6 inhibitor plus an aromatase inhibitor. Read More ›
Dr Hope Rugo addresses some of the main differences between the 3 CDK4/6 inhibitors that are FDA-approved in HR-positive metastatic breast cancer. Read More ›
Dr Hope Rugo cites that CDK4/6 inhibitors play a critical role in estrogen signaling and can be very effective in treating metastatic breast cancer when used in combination with hormone therapy. Read More ›
The WCGIC chairperson, professor Eric Van Cutsem, MD, PhD, heads the Division of Digestive Oncology at University Hospitals Leuven and KU Leuven, Leuven, Belgium. He describes the difference between left- and right-sided colon cancers in terms of prognosis and response to therapy. Read More ›